(Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. 04, 2021 (GLOBE NEWSWIRE) - Vir Biotechnology, Inc. – Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD and initial HIV vaccine immunology data – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized – – To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide –
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |